Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Havrdova

Showing results (21-30 of 124) with videos related to

Pageof 13
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosisRafael Arroyo González, Mariko Kita, Heidi Crayton, et al.
Expert Opinion on Pharmacotherapy|August 27, 2013
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97Eva Havrdova, Michael Hutchinson, Nuwan C Kurukulasuriya, et al.
Neurology|January 24, 2014
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 studyPer S Sorensen, Steen Lisby, Richard Grove, et al.
Neurology and Therapy|July 15, 2016
Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study ProgramRalf Gold, Dusan Stefoski, Krzysztof Selmaj, et al.
Neuroimage. Clinical|July 15, 2017
Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosisMichael G Dwyer, Diego Silva, Niels Bergsland, et al.
Multiple Sclerosis and Related Disorders|September 23, 2022
Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 yearsDevon Oship, Dejan Jakimovski, Niels Bergsland, et al.
Journal of Neuroimmunology|August 12, 2014
Complement activation in patients with neuromyelitis opticaPetra Nytrova, Eliska Potlukova, David Kemlink, et al.
JAMA Neurology|September 3, 2014
The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosisJeffrey A Cohen, Arun V Krishnan, Andrew D Goodman, et al.
Brain and Behavior|March 16, 2017
MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patientsJana Libertinova, Eva Meluzinova, Vaclav Matoska, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2016
Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?Tomas Uher, Eva Havrdova, Lukas Sobisek, et al.
Pageof 13

Showing results (21-30 of 124) with videos related to

Sort By:
Pageof 13
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 26, 2016
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosisRafael Arroyo González, Mariko Kita, Heidi Crayton, et al.
Expert Opinion on Pharmacotherapy|August 27, 2013
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM. Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107; and Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97Eva Havrdova, Michael Hutchinson, Nuwan C Kurukulasuriya, et al.
Neurology|January 24, 2014
Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 studyPer S Sorensen, Steen Lisby, Richard Grove, et al.
Neurology and Therapy|July 15, 2016
Pregnancy Experience: Nonclinical Studies and Pregnancy Outcomes in the Daclizumab Clinical Study ProgramRalf Gold, Dusan Stefoski, Krzysztof Selmaj, et al.
Neuroimage. Clinical|July 15, 2017
Neurological software tool for reliable atrophy measurement (NeuroSTREAM) of the lateral ventricles on clinical-quality T2-FLAIR MRI scans in multiple sclerosisMichael G Dwyer, Diego Silva, Niels Bergsland, et al.
Multiple Sclerosis and Related Disorders|September 23, 2022
Assessment of T2 lesion-based disease activity volume outcomes in predicting disease progression in multiple sclerosis over 10 yearsDevon Oship, Dejan Jakimovski, Niels Bergsland, et al.
Journal of Neuroimmunology|August 12, 2014
Complement activation in patients with neuromyelitis opticaPetra Nytrova, Eliska Potlukova, David Kemlink, et al.
JAMA Neurology|September 3, 2014
The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosisJeffrey A Cohen, Arun V Krishnan, Andrew D Goodman, et al.
Brain and Behavior|March 16, 2017
MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patientsJana Libertinova, Eva Meluzinova, Vaclav Matoska, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 28, 2016
Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up?Tomas Uher, Eva Havrdova, Lukas Sobisek, et al.
Pageof 13